Allergan Given a $123.00 Price Target by Credit Suisse Analysts (AGN)
Analysts at Credit Suisse set a $123.00 price objective on shares of Allergan (NYSE:AGN) stock in a research report issued to clients and investors on Friday, StockRatingsNetwork reports. Credit Suisse’s price objective would indicate a potential upside of 11.53% from the company’s current price.
In other Allergan news, VP Julian Gangolli sold 52,500 shares of the stock on the open market in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $110.05, for a total value of $5,777,625.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other firms have also recently commented on AGN. Analysts at Wells Fargo & Co. upgraded shares of Allergan from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday, December 24th. Separately, analysts at BMO Capital Markets raised their price target on shares of Allergan from $112.00 to $117.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Allergan from $100.00 to $116.00 in a research note to investors on Friday, December 20th. They now have a “buy” rating on the stock. Ten analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $110.43.
Shares of Allergan (NYSE:AGN) opened at 110.28 on Friday. Allergan has a 52 week low of $81.33 and a 52 week high of $116.45. The stock has a 50-day moving average of $99.91 and a 200-day moving average of $92.56. The company has a market cap of $32.771 billion and a P/E ratio of 33.43. Allergan also was the recipient of unusually large options trading activity on Tuesday. Traders purchased 3,502 put options on the stock. This represents an increase of approximately 103% compared to the average volume of 1,729 put options.
Allergan (NYSE:AGN) last released its earnings data on Tuesday, October 29th. The company reported $1.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.20 by $0.03. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The company’s quarterly revenue was up 13.3% on a year-over-year basis. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.